TRIUMPH-1: Retatrutide Phase 3 trial (NCT05929066)
A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)
At a glance
- Phase
- Phase 3
- Status
- Completed
- Enrolment
- 2,335
- actual
- Start
- 10 Jul 2023 (actual)
- Primary completion
- 6 Apr 2026 (actual)
- Sponsor
- Eli Lilly and Company
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Retatrutide Dose 1 | Experimental | Drug: Retatrutide | Participants will receive retatrutide subcutaneously (SC). |
| Retatrutide Dose 2 | Experimental | Drug: Retatrutide | Participants will receive retatrutide SC. |
| Retatrutide Dose 3 | Experimental | Drug: Retatrutide | Participants will receive retatrutide SC. |
| Placebo | Placebo comparator | Drug: Placebo | Participants will receive placebo. |
| Retatrutide Extension Period | Experimental | Drug: Retatrutide | Participants will receive retatrutide after the placebo-controlled 80 week treatment period for an additional 24 weeks. |
Primary endpoint
| Measure | Time frame |
|---|---|
| Percent Change From Baseline in Body Weight | Baseline, Week 80 |
| Change from Baseline in Apnea-Hypopnea Index (AHI) Events Per Hour for GSA1 Subset | Baseline, Week 80 |
| Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score for GOA1 Subset | Baseline, Week 80 |
| Percent Change from Baseline in Body Weight in Participants in Extension Subset | Baseline, Week 104 |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight in Participants with Baseline BMI ≥ 35 kg/m2 | Baseline, Week 80 |
| Percentage of Participants who Achieve Body Weight Reduction of ≥ 5% | Baseline through Week 80 |
| Percentage of Participants who Achieve Body Weight Reduction of ≥ 10% | Baseline through Week 80 |
| Percentage of Participants who Achieve Body Weight Reduction of ≥ 15% | Baseline through Week 80 |
| Percentage of Participants who Achieve Body Weight Reduction of ≥ 20% | Baseline through Week 80 |
| Percentage of Participants who Achieve Body Weight Reduction of ≥ 25% | Baseline through Week 80 |
| Percentage of Participants who Achieve Body Weight Reduction of ≥ 30% | Baseline through Week 80 |
| Percentage of Participants who Achieve Body Weight Reduction of ≥ 35% | Baseline through Week 80 |
| Change from Baseline in Waist Circumference | Baseline, Week 80 |
| Change from Baseline in Systolic Blood Pressure (SBP) | Baseline, Week 80 |
| Percent Change from Baseline in Triglycerides | Baseline, Week 80 |
| Percent Change from Baseline in Non-High-Density Lipoprotein (HDL)-Cholesterol | Baseline, Week 80 |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- Not stated
Results
No results posted on ClinicalTrials.gov as of 2 Oct 2026.
TRIUMPH-1 as published for retatrutide in adults with obesity
Adults with obesity but not diabetes were assigned weekly retatrutide at 4, 9 or 12 mg, or placebo, for 80 weeks.[2]
Mean percent change in body weight was -17.6% (4 mg), -23.7% (9 mg) and -25.0% (12 mg) against -3.9% on placebo.[2]
In participants with knee osteoarthritis, WOMAC pain scores changed by -3.2, -3.5 and -3.6 against -1.9 on placebo for the hybrid estimand.[2]
Primary outcomes also covered the apnea-hypopnea index in the 243 participants with obstructive sleep apnea.[2]
Sources
- 1A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)ClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
- 2Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.The New England journal of medicine · 2026PMID 42814954Accessed 2 Oct 2026
Found an error? Report a correction.